Q-omics provides the consensus-scored AMBN profile across patient tissues and cancer cell-line models. AMBN expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in PCPG. Among the 18 cancer types available for tumor–normal comparison, AMBN is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, AMBN RNA expression shows 6,597 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PCPG, UCEC, and STAD as cancer lineages where AMBN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMBN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMBN survival associations across molecular data types. AMBN RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMBN RNA expression–survival associations across cancer types. High AMBN expression shows unfavorable associations in PCPG, CESC, SKCM, KIRC and LIHC, but favorable associations in SCLC. The PCPG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PCPG as the clearest survival context for AMBN RNA expression.
This table summarizes AMBN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 1. The strongest signals are observed in UCEC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for AMBN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMBN shows higher tumor expression in UCEC, STAD, KICH and PRAD. The UCEC box plot shows higher AMBN RNA expression in tumor versus normal tissue (log2 FC = +0.648, t-test p = .014).
This table shows molecular features associated with AMBN in patient tissues and cancer cell lines. In patient samples, AMBN shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, AMBN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
